29.93USD+0.27%Mkt Cap: 2.49B USDP/E: —Last update: 2026-05-26
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered,…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap2.49B USD
Enterprise Value1.85B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-154.65M USD
Revenue/Share—
Last Price29.93 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees76
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.57
PEG—
EV/EBITDA-10.78
EV/Revenue—
P/S—
P/B3.81
EPS (TTM)-1.97
EPS (Forward)-1.94
52W Range
12.5949% of range47.65
52W High47.65 USD
52W Low12.59 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.91%
ROA-23.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-142.42M USD
CapEx (TTM)15.00K USD
FCF Margin—
FCF Yield-3.16%
Net Debt-646.06M USD
Net Debt/EBITDA3.77
Balance Sheet
Debt/Equity—
Current Ratio44.33
Quick Ratio43.90
Book Value/Sh7.931 USD
Cash/Share7.831 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)48.50 USD
Target Range30.00 USD – 56.00 USD
# Analysts8
Ownership
Shares Out.82.50M
Float60.37M
Insiders0.72%
Institutions116.48%
Short Interest
Short Ratio7.3d
Short % Float12.56%
Short % Out.10.34%
Shares Short8.53M
Short (prev mo.)8.37M
Technical
SMA 5027.19 (+10.1%)
SMA 20032.02 (-6.5%)
Beta0.48
S&P 52W Chg28.31%
Avg Vol (30d)1.14M
Avg Vol (10d)1.22M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—